ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Sequentially Responsive Three-Lobed Supramolecular Platform for Tumor Microenvironment Remodeling and Blood-Brain Barrier Penetration.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioblastoma (GBM) therapy is severely hindered by the inflammatory tumor microenvironment (TME) and insufficient penetration of biological barriers, which lead to poor therapeutic efficacy and severe side effects. Herein, we rationally designed and constructed a novel three-lobed supramolecular delivery platform via π-π stacking and covalent cross-linking, which enables enhanced responsiveness to the inflammatory TME and superior blood-brain barrier penetration for multi-modal synergistic GBM therapy. Notably, this platform exhibits a sequential response to the inflammatory TME characterized by high ROS levels and acidic pH, thereby achieving on-demand drug release, as well as efficient targeted accumulation across biological barriers. Furthermore, it exerts potent synergistic anti-tumor effects through near infrared (NIR) photothermal ablation, chemotherapy, and JAG1/NOTCH1 signaling pathway inhibition, while maintaining excellent in vivo biocompatibility without obvious damage to normal tissues and organs. This multi-module supramolecular assembly strategy provides a gradually progressive approach for precise therapy by anchoring the pathological characteristics, thereby advancing the revolutionary iteration of the GBM treatment system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.